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Lambert—Eaton syndrome (LES) is a presynaptic disorder
characterized by impaired quantal release of acetylcholine
(ACh) at the neuromuscular junction (Elmqvist & Lambert,
1968). LES is often associated with small-cell lung cancer
(SCLC; O’Neill, Murray & Newsom-Davis, 1988), a
neuroendocrine tumour that expresses neuronal voltage-
dependent Ca¥ channels (VDCCs; Viglione, O’Shaughnessy
& Kim, 1995). Current evidence supports the idea that the
syndrome, which has an autoimmune origin, is a result of
the inhibition of presynaptic VDCCs by the channel-specific
autoantibodies (reviewed in Vincent, Lang & Newsom-
Davis, 1989; Wray, 1990). Although the precise immuno-
gen(s) has not yet been determined, an autoimmune
response against tumour antigen(s) is thought to trigger the
production of pathogenic autoantibodies (Roberts, Perera,
Lang, Vincent & Newsom-Davis, 1985; Viglione et al. 1995).
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1. The types of voltage-dependent calcium channels (VDCCs) present in the cholinergic
terminals isolated from the electric organ of the ray, Narke japonica, were characterized on
the basis of their pharmacological sensitivity to specific antagonists. Inhibition of these
channel types by autoantibodies from patients with the Lambert—Eaton syndrome (LES)
was then studied to determine the specificity of the pathogenic IgG.
2. In normal untreated synaptosomal preparations, maximal doses of N- and P andÏor Q-type
Ca¥ channel antagonists, ù-conotoxin GVIA and ù-agatoxin IVA, inhibited depolarization-
evoked ACh release by 47% and 43%, respectively. Calciseptine, an L-type VDCC
antagonist, caused a 20% reduction in the release. This indicates that the exocytotic release
process is predominantly mediated by N- and PÏQ-type VDCCs.
3. LES IgG or sera caused an inhibition of ACh release by 39—45% in comparison with the
control antibody-treated preparations. The ionomycin-induced ACh release, however, was
not altered by the antibodies. Additionally, the same LES antibodies inhibited whole-cell
calcium currents (ICa) in bovine adrenal chromaffin cells. Thus, the pathogenic antibodies
exert their action on VDCCs present in the synaptosomes.
4. The efficacy of three Ca¥ channel antagonists in blocking ACh release was determined in
preparations pretreated with LES IgG. ù-Agatoxin IVA produced only an additional 3—5%
reduction in release beyond that obtained with LES antibodies. Despite the pretreatment
with LES IgG, ù-conotoxin GVIA and calciseptine inhibited the release to nearly their
control levels.
5. These results indicate that LES antibodies mainly downregulate PÏQ-type Ca¥ channels
which contribute to presynaptic transmitter release from the cholinergic nerve terminals of
electric organ.
6. The present findings are consistent with the hypothesis that PÏQ-type VDCCs at the neuro-
muscular junction are the target of LES antibodies and that their inhibition by the anti-
bodies produces the characteristic neuromuscular defect in this disease.
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Morphological and electrophysiological studies collectively
support the view that the LES antibodies downregulate the
presynaptic Ca¥ channels mediating exocytotic release of
ACh from the motor nerve terminal. In freeze-fracture
electron micrographs of presynaptic membranes of the
neuromuscular junctions of LES patients (Fukunaga, Engel,
Osame & Lambert, 1982), active zone particles, hypothesized
to be VDCCs, were spatially disorganized and fewer in
number. Exposure of cultured neuronal and endocrine cells
to IgG from LES patients causes a pronounced reduction in
whole-cell currents carried by VDCCs (Kim & Neher, 1988;
Peers, Lang, Newsom_Davis & Wray, 1990; Grassi,
Magnelli, Carabelli, Sher & Carbone, 1994; Garcia & Beam,
1996; Meriney, Hulsizer, Lennon & Grinnell, 1996).
Individual channel activation kinetics and conductance were
unchanged, however, indicating that the pathogenic IgG
acts to downregulate the number of functional channels
(Kim & Neher, 1988; Grassi et al. 1994). LES antibodies also
reduce depolarization-induced uptake of
45
Ca¥ by SCLC
cell lines (Roberts et al. 1985; De Aizpurua, Lambert,
Griesman, Olivera & Lennon, 1988). As with antibodies
against acetylcholine receptors (AChRs) in myasthenia
gravis (MG), antigenic modulation and cross-linking of the
channels are the events associated with pathogenic action of
LES IgG (Peers, Johnston, Lang &Wray, 1993).
Serological studies have also revealed the pathogenic
interaction of LES autoantibodies with specific VDCCs. LES
IgG can immunoprecipitate N-type VDCCs labelled with
[
125
I]ù-conotoxin GVIA from chick and rat brain
synaptosomes (Martin-Moutot, Lang, Newsom-Davis &
Seager, 1995), human neuroblastoma cells (Sher et al. 1989)
and SCLC cells (De Aizpurua et al. 1988). More recent work,
however, indicates that 95% of LES patients possess anti-
bodies which immunoprecipitate P andÏor Q-type VDCCs
labelled with [
125
I]ù-conotoxin MVIIC (Lennon et al. 1995).
Despite overwhelming evidence for an autoimmune patho-
genesis, no animal model of LES, such as that so well
established for MG (Lindstrom, 1979), has been fully
developed and characterized. In human myasthenia gravis,
a postjunctional disorder of the skeletal neuromuscular
junction, AChR proteins isolated from postsynaptic
membranes of Torpedo electric organ have served as a highly
valuable antigen in inducing the anti-AChR antibody
production. In an attempt to produce a similar animal
model by active immunization, we have recently immunized
mice and rats with Narke japonica synaptosomes containing
cholinergic presynaptic nerve terminals (Kim et al. 1998).
Consistent with the presynaptic impairment characterizing
LES, neuromuscular junctions in these immunized animals
exhibit a reduction in the quantal content of nerve-evoked
end-plate potentials (EPPs). In a previous study (Chapman,
Rabinowitz, Korczyn & Michaelson, 1990), animals injected
with similar cholinergic synaptosomes from Torpedo were
also found to develop electromyographic signs of the
syndrome. These studies, however, were not able to address
which components of the synaptosome are involved in the
autoimmune disease process. The absence of such
information thus provides further impetus to identify and
characterize the putative Ca¥ channel antigens contained in
these electric ray synaptosomes.
The aim of the present study is threefold. First is to
characterize the types of Ca¥ channels present in the
electric organ synaptosomes of the Japanese electric ray,
Narke japonica. Second is to provide direct evidence that
LES autoantibodies reduce the depolarization-induced ACh
release from these synaptosomes. Third, we explored which
types of Ca¥ channels are impaired by LES autoantibodies,
thus suggesting the type(s) implicated in the disease process.
Synaptosomes from electric organs used in the present work
consist of pure cholinergic nerve terminals and are free from
postsynaptic membranes. The ACh release characteristics in
this preparation are similar to those at the neuromuscular
junction (Dunant & Muller, 1986). Thus the results obtained
using the synaptosomes are likely to be relevant to the
neuromuscular junction. Furthermore, our ability to assess
the reduction in ICa by LES antibodies in bovine adrenal
chromaffin cells and to correlate this reduction with the
inhibition of synaptosomal ACh release provides compelling
evidence that LES antibodies interact with Ca¥ channels
functionally coupled to the transmitter release. In addition
to their value in the induction of experimental autoimmune
Lambert—Eaton syndrome, cholinergic nerve terminals of
electric organ appear to be an ideal system with which to
assess directly the action of LES IgG on cholinergic
transmitter release.
METHODS
Chemicals
Horseradish peroxidase, acetylcholine chloride, luminol and
3_aminobenzoic acid ethyl ester methanesulphonate (tricaine) were
obtained from Sigma (USA). Choline oxidase was purchased from
Funakoshi (Tokyo, Japan) and peroxidase (from Arthromyces
ramous) from Nakalai Tesque (Kyoto, Japan). Ionomycin was from
Calbiochem (USA). Synthetic ù-conotoxin GVIA (ù-CgTX GVIA),
ù-conotoxin MVIIC (ù-CTX MVIIC), ù-agatoxin IVA (ù-AgTX
IVA) and calciseptine were obtained from Peptide Institute (Osaka,
Japan).
Preparation of electric organ synaptosomes
Preparation of synaptosomes from electric organ was carried out at
4°C using sucrose density gradient centrifugation as described
previously (O’Hori et al. 1993). Japanese electric rays, Narke
japonica, were captured off the coast of Nagasaki and Fukuoka
Prefectures, Japan, and were kept alive in artificial sea water
(Yashima, Osaka, Japan) until use. After anaesthesia with 0·03%
tricaine, fish (typically 5) were dissected to isolate electric organs.
Finely chopped organs were suspended in modified physiological
medium (MPM) containing the following (mÒ): 285·1 NaCl, 3 KCl,
1·8 MgClµ, 100 sucrose, 5·5 glucose, 300 urea and 40 Na-Hepes
(pH 7·4). The suspension was stirred for 30 min and successively
passed through nylon mesh with square openings of 1000, 500, 200
and 50 ìm. The filtrate was centrifuged at 6 000 g for 20 min. The
Y. Satoh and others J. Physiol. 508.2428
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pellet was resuspended in physiological medium and layered on top
of a stepwise sucrose density gradient. The constituents of each
layer from the top were as follows: MPM containing 0·1 Ò urea and
0·3 Ò sucrose instead of 0·3 Ò urea and 0·1 Ò sucrose; and MPM
containing 0·5 Ò sucrose instead of 0·3 Ò urea and 0·1 Ò sucrose.
Centrifugation was performed at 63 000 g for 40 min. The band at
the interface of 0·1 Ò urea plus 0·3 Ò sucrose and 0·5 Ò sucrose was
collected and centrifuged at 95 500 g for 60 min. The pellet was
resuspended in MPM and used for experiments within 12 h.
Continuous measurement of acetylcholine release
ACh release from synaptosomes evoked by depolarization with high
concentrations of KCl was measured continuously at physiological
pH 7·4 using the chemiluminescence method, according to
Schweitzer’s modification (Schweitzer, 1987) of the original method
by Israel & Lesbats (1981). We previously confirmed that under our
experimental conditions described below, light output was linear
with respect to the amount of ACh over the range investigated
(O’Hori et al. 1993).
The procedure for the measurement of ACh released from
synaptosomes untreated with IgGs was as follows: a 30 ìl
suspension of synaptosomes in MPM (about 1 mg ml¢ protein) was
mixed with an MPM solution (120 ìl) containing the chemi-
luminescence agents (choline oxidase, peroxidase, luminol) and
4·25 mÒ CaClµ, with or without the addition of Ca¥ channel
blockers. After incubation in a cuvette of a photometer
(Lumicounter 1000, Niti-on, Funabashi, Japan) at 25°C for 20 min,
the depolarization stimulus was applied by injection of 100 ìl
isotonic high [K¤]ï solution (mÒ): 37·5 NaCl, 245·5 KCl, 1·8 MgClµ,
5·5 glucose, 3·4 CaClµ, 50 urea, 400 sucrose and 40 Na-Hepes,
pH 7·4, with a microsyringe through a rubber septum. The
photometer is equipped with a device that rotates the cuvette
horizontally and reciprocally, which ensures a complete mixing of
the contents in the cuvette. The final composition of the contents
(250 ìl) in the cuvette was about (mÒ): 0·06 luminol, 183 NaCl,
100 KCl, 1·8 MgClµ, 3·4 CaClµ, 5·5 glucose, 50 urea, 400 sucrose
and 40 Na-Hepes (pH 7·4); 120 ìg ml¢ protein, 20 U ml¢ choline
oxidase and 20 ìg ml¢ peroxidase.
The procedure for the measurement of ACh released from IgG-
treated synaptosomes was as follows: a 30 ìl suspension of
synaptosomes in MPM (about 1·2 mg ml¢ protein) was mixed with
an MPM solution (120 ìl) containing the chemiluminescence agents
(choline oxidase, peroxidase, luminol) and 4·25 mÒ CaClµ, with the
addition of LES IgG or serum. After incubation for 70 min at 25°C,
the suspension was mixed with 30 ìl of MPM or MPM containing
Ca¥ channel blockers and incubated for another 20 min. Then, to
induce depolarization, 120 ìl of isotonic high [K¤]ï solution of the
same composition as above was injected into the sample. The final
composition of the contents (300 ìl) was the same as above except
for the presence of IgG or serum. The amount of ACh released was
determined from the area under the peak of the chemiluminescence
curve, as compared with that of standard ACh added to the sample
at the end of measurement.
Preparation of LES serum and IgG
Three LES patients, whose serological samples were utilized in the
present study, were clinically and electromyographically diagnosed
as having LES. Patients 1 and 2 (from the University of Virginia
Hospital) had associated small-cell lung cancer and their samples
were identified as having antibodies capable of inhibiting ICa in
patch-clamp studies (see Results). Patient 3 (from Toneyama
Hospital, Osaka, Japan) also manifested SCLC which was
confirmed at autopsy; this patient’s serum was not assayed for its
effect on ICa.
LES plasma, collected during plasma exchange therapy from
patients 1 and 2, was converted to serum by Ca¥-induced
precipitation of clotting factors. Immunoglobulin G was isolated
from plasma using the Rivanol precipitation method. Blood was
withdrawn by venipuncture from patient 3 and allowed to clot at
room temperature (22—25°C) and then serum was obtained by
centrifugation at 700g for 10 min. The serum or IgG was then
dialysed for 48 h against the culture medium with a dialysate
change at 24 h. Concentration of IgG was determined by rate flow
nephelometry in the Clinical Immunology Laboratory. Control
plasma (from healthy individuals) was obtained from the University
of Virginia blood bank, and control serum or IgG prepared as
described above.
All human serological samples and the synaptosomal preparations
used in this study were obtained in conformity with the guidelines
established by the institutional Human and Animal Investigation
Committees at the University of Tokyo and University of Virginia.
Patch-clamp study of the effects of LES IgG on whole-cell
calcium currents
We used standard patch-clamp techniques to record voltage-
dependent Ca¥ and Na¤ currents (Hamill, Marty, Neher, Sakmann
& Sigworth, 1981) from bovine adrenal chromaffin cells using a List
EPC_7 patch-clamp amplifier (List Electronics, Darmstadt,
Germany). Preparation of the cultured cells and patch-clamp
recording procedures are the same as described elsewhere (Kim &
Neher, 1988). The following solutions were used for all patch-clamp
recordings of ICa. The internal or pipette solution contained (mÒ):
1 CaClµ, 2 MgClµ, 120 CsCl, 11 Na-EGTA, 20 TEACl, 10 Na_Hepes
(pH 7·2). For most patch-clamp recordings, the bath contained
(mÒ): 130 NaCl, 5 KCl, 1 CaClµ, 5 glucose, 10 Na-Hepes (pH 7·2).
A 20 mV test potential applied from the holding potential at a rate
of 5 Hz was used to monitor the establishment of the gigaohm seal.
After seal formation, values for membrane capacitance (Cm) and
access resistance (Rs) were obtained by cancellation of the transient
current with the EPC_7. Measurements were initiated 1 min after
achieving the whole-cell configuration and all experiments were
performed at room temperature (22—25°C).
Data collection and statistics
In most of the synaptosome studies, chemiluminescence
measurements of ACh release were repeated five times for each
preparation under a particular test condition. In each patch-clamp
experiment, ICa was sampled from eight to twelve bovine adrenal
chromaffin cells subjected to incubation with control or LES
IgGÏserum. All data were pooled for each experimental condition
and presented as means ± s.e.m. of all measurements. Statistical
significance of the difference between the two means was tested
using Student’s t test. Unless otherwise noted, P values less than
0·05 were considered to be statistically significant.
RESULTS
Pharmacological characterization of VDCCs in electric
organ synaptosomes
Utilizing the sensitivity to Ca¥ channel blockers specific to
subtypes of VDCCs, we characterized the VDCCs of electric
organ synaptosomes from the Japanese electric ray, Narke
japonica, a member of Torpedinidae family. When
LES IgG inhibits PÏQ-type Ca¥ channelsJ. Physiol. 508.2 429
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synaptosomes were depolarized, ACh was released in a
manner dependent on the strength of depolarization and on
the extracellular Ca¥ concentration. Throughout the present
study, depolarization was induced by increasing
extracellular K¤ concentration from 3 to 100 mÒ in the
presence of 3·4 mÒ extracellular Ca¥.
The presence of N-type VDCCs sensitive to ù-CgTX GVIA
in the electric organ synaptosomes has been established
(Ahmad & Miljanich, 1988; Farin˜as, Solsona & Marsal,
1992; O’Hori et al. 1993). The ù-CgTX GVIA-sensitive
VDCC pharmacologically identified in these studies appears
to correspond to the expression of a cDNA clone, doe-4, for
the á1-subunit of a putative VDCC from the electric lobe
(Horne, Ellinor, Inman, Zhou, Tsien & Schwarz, 1993). The
sequence of doe-4 has about a 70% homology with that of the
mammalian B subclass which corresponds to the á1_subunit
of the N-type VDCC. This provides a rationale for the use
of the same criteria applied for mammalian preparations in
classifying the Ca¥ channel types in electric fish.
The dose—inhibition curve obtained after exposing the
synaptosomes to varying concentrations of ù-CgTX GVIA is
illustrated in Fig. 1A. When fitted by a Michaelis—Menten-
type equation, the curve gave rise to a half-inhibition
concentration (IC50) of 7·5 ìÒ and maximum inhibition (Imax)
of 47%. In electric organ synaptosomes, the dissociation
constant (Kd) of ù-CgTX GVIA with N_type VDCCs is
several micromolars (O’Hori et al. 1993), similar to the
observed IC50 in this study. More than 50% of ACh release
was not blocked by ù-CgTX GVIA, suggesting that the
remaining release may be due to Ca¥ influx through
ù_CgTX GVIA-insensitive VDCCs.
To determine the expression of P-type VDCCs in the Narke
japonica nerve terminals, we examined the effect of
ù_AgTX IVA, a P-type VDCC-specific antagonist (Mintz,
Adams & Bean, 1992). Shown in Fig. 1B is the
dose—inhibition relationship with ù-AgTX IVA, from
which IC50 at 2·6 ìÒ and Imax of 43% were derived.
ù_AgTX IVA, at concentrations higher than 200 nÒ has
Y. Satoh and others J. Physiol. 508.2430
Figure 1. Inhibition of high [K¤]ï-induced ACh release in electric
organ synaptosomes by Ca¥ channel antagonists
ù-CgTX GVIA (A), ù-AgTX IVA (B) and ù-CTXMVIIC (C) block
transmitter release from the cholinergic nerve terminals in a dose-
dependent manner. Each value is the mean ± s.e.m. (bars) from at least
3 independent determinations. The continuous line is a curve best fitted
using a Michaelis—Menten type equation with IC50 = 7·5 ìÒ,
Imax = 47·0% for A; IC50 = 2·6 ìÒ, Imax = 42·5% for B ; and
IC50 = 3·8 ìÒ, Imax = 77·1% for C.
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been found to partially block Q-type VDCCs (Sather,
Tanabe, Zhang, Mori, Adams & Tsien, 1993). The difference
between Q- and P-types of VDCCs seems to be the
concentrations at which ù-AgTX IVA block these channels.
Since the affinity of ù-AgTX IVA in electric organ
synaptosomes is much lower than that in mammalian
preparations, it is difficult to determine if the VDCC in
electric organ synaptosomes inhibited by the micromolar
concentrations of ù-AgTX IVA is of P- or Q-type. Therefore,
we have designated ù-AgTX IVA-sensitive VDCCs of the
electric organ synaptosomes as ‘PÏQ-type’ VDCCs.
Next, we examined whether or not the inhibitory effect of
ù-AgTX IVA is independent of that of ù-CgTX GVIA.
When ù-AgTX IVA at 30 ìÒ was applied together with a
maximal concentration of ù-CgTX GVIA (50 ìÒ), the K¤-
evoked ACh release was inhibited by 69·9 ± 2·2% (mean ±
s.e.m., n = 3, three different experimental runs using a
single preparation) while 50 ìÒ ù-CgTX GVIA alone
exerted 47·0 ± 4·2% inhibition (n = 5). The additional
inhibition of ù-AgTX IVA over ù-CgTX GVIA indicates a
different site of action of ù-AgTX IVA from that of the
N_type VDCC (Fig. 2).
Although ù-CTX MVIIC is usually assumed to be a P-type-
specific VDCC antagonist, it inhibits not only P- but also
N_type VDCCs at high concentrations (Turner, Lampe &
Dunlap, 1995). Accordingly, ù-CTX MVIIC at its maximum
dose is expected to produce a greater effect than the
maximum inhibition by ù-CgTX GVIA or ù-AgTX IVA.
Figure 1C shows the dose-dependent blockade of the ACh
release by ù-CTX MVIIC. When applied at the maximum
dose, the toxin blocked ACh release by 71%, a value
exceeding the maximum effect of either ù-CgTX GVIA or
ù-AgTX IVA. Addition of either ù-CgTX GVIA or
ù_AgTX IVA to synaptosomes pretreated with ù-CTX
MVIIC yielded no further reduction (Fig. 2). These results
strongly suggest that ù-CTX MVIIC inhibits both N- and
P-type VDCCs of the electric organ synaptosomes.
Therefore, ù-AgTX IVA, not ù-CTX MVIIC, was used in
the following experiments to discriminate PÏQ-type and
N_type VDCCs.
Although L-type VDCC is also involved in cholinergic
transmitter release from electric organ synaptosomes, its
contribution is smaller than those of N- or PÏQ-type VDCC
(Tokumaru, Satoh, Hirashima, Shojaku, Yamamoto &
Kirino, 1997). Calciseptine, a potent inhibitor of L-type
VDCCs, maximally depressed the K¤-evoked ACh release
by only about 20%. This is in accord with our previous data
(Tokumaru et al. 1995) demonstrating inhibition by a
monoclonal antibody against the áµä-subunit of L-type
VDCC and provides evidence for involvement of the L-type
VDCCs in ACh release. Calciseptine caused additional
depression of ACh release from synaptosomes treated with
ù-AgTX IVA and ù-CgTX GVIA (Fig. 2). Therefore, the
three toxins used in this study inhibit ACh release
independently, acting on different subtypes of VDCCs.
Effects of LES IgG on ACh release
Prior to high K¤ stimulation, synaptosomes were pre-
incubated at 25°C for varying time periods with serum
from LES patient 1 or with control (disease-free) human
serum. Upon incubation with control serum (0·5 mg ml¢
IgG) for 90 min, the synaptosomes released a total ACh of
71·3 ± 5·1 pmol (n = 3; Fig. 3A). The equivalent amount
of ACh released in preparations incubated with LES
serum (patient 1, 0·5 mg ml¢ IgG) was distinctively
lower: 34·0 ± 4·3 pmol (n = 3, P < 0·01). The time course
of the inhibitory action of LES serum on ACh release is
shown in Fig. 3B. After 75 min of incubation, we observed
maximal inhibition of about 50%, as compared with the
release from synaptosomes incubated with serum from
healthy individuals.
In a different synaptosomal preparation incubated for
90 min with the same LES serum, we also observed a
decrease in the amount of ACh released to 53·8 ± 5·1 pmol
(n = 5, 45% of control, P < 0·0001) from control value of
119·2 ± 3·5 pmol (incubated with control serum for 90 min,
n = 5).
We further confirmed the antibody-induced inhibition of
cholinergic transmitter release using serum from two
additional LES patients. After 90 min of incubation, IgG
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Figure 2. Inhibitory effects of various
combinations of Ca¥ channel blockers
on evoked ACh release from
synaptosomes
Concentration of antagonists was 30 ìÒ
for calciseptine, ù-AgTX IVA and ù-CTX
MVIIC, and 50 ìÒ for ù-CgTX GVIA.
Each value represents the mean ± s.e.m.
(bars) from at least 3 determinations.
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(1 mg ml¢) from patient 2 markedly diminished ACh
release to 46·4 ± 3·7 pmol (n = 5, 39% of control,
P < 0·0001). Likewise, ACh liberated upon exposure to
serum from patient 3 with the same IgG concentration was
significantly smaller, 49·5 ± 2·9 pmol (n = 5; 42% of
control; P < 0·0001).
Effects of LES IgG on ionomycin-induced release of
ACh
The reduction in cholinergic transmitter release by LES IgG
may be caused by altered intracellular Ca¥ homeostasis or
exocytotic secretion. In view of this possibility, we
determined whether the pathological antibodies act on steps
beyond Ca¥ influx through VDCCs. To this end, we used
the ionophoric polyether antibiotic, ionomycin, which
selectively increases membrane permeability to Ca¥ ions,
facilitating Ca¥ influx independent of VDCCs. Synapto-
somes incubated with serum (0·5 mg ml¢ IgG) from LES
patient 1 or a healthy individual were stimulated with 1 mÒ
ionomycin. As shown in Fig. 4, there was little difference in
the release profiles between the two, signifying that LES
IgG failed to interfere with the ionomycin-induced release
of ACh. These findings thus indicate that the cholinergic
Y. Satoh and others J. Physiol. 508.2432
Figure 3. LES IgG diminishes evoked ACh release from electric organ synaptosomes
Synaptosomes were incubated with LES serum (0·5 mg ml¢ IgG) at 25°C and then depolarized by
injection of the high [K¤]ï solution to increase K¤ concentration in the medium from 3 to 100 mÒ. The
experiments were carried out using a single preparation of synaptosomes. The ACh released was measured
by the chemiluminescence method. See Methods for details. A, chemiluminescence output from electric
organ synaptosomes incubated for 90 min with sera from LES patient 1 or control subject. In this particular
example, ACh released was 73·6 pmol (Control) and 37·6 pmol (LES). Arrow indicates the time high [K¤]ï
stimulation was applied. B, the time course of the inhibitory action of LES IgG on ACh release from electric
organ synaptosomes. The effects of LES (1) and control (±) sera (0·5 mg ml¢ IgG) on ACh release were
plotted as a function of incubation time. Notice that inhibition reaches maximum after about 60 min of
incubation. The decrease of ACh release in control (and in LES in part) is due to incubation of the
synaptosomes at a high temperature (22—25°C). Each value is the mean ± s.e.m. (bars) from 5 independent
determinations. *P < 0·05 and **P < 0·01, by Student’s t test compared with control at the same
incubation time.
Figure 4. LES IgG has no effect on ionomycin-evoked transmitter
release
Synaptosomes were incubated for 90 min with serum (0·5 mg ml¢ IgG) from
LES patient 1 or a control healthy individual, followed by stimulation with 1 mÒ
ionomycin. Little difference in the amount of released ACh was observed
between LES and control serum-treated terminals. Arrow indicates the time
ionomycin was applied.
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terminals treated with LES IgG are capable of producing
normal secretory activity when sufficient Ca¥ ions become
available intracellularly. This in turn supports the notion
that LES IgG impairs neither intracellular Ca¥ metabolism
nor the ACh secretory machinery.
LES IgG inhibits ICa in chromaffin cells
With the purpose of correlating the synaptosomal effects
with the functional inhibition of VDCCs, we explored
whether antibodies from patients 1 and 2 were capable of
inhibiting ICa in bovine adrenal chromaffin cells. Bovine
adrenal chromaffin cells are a well-studied neuroendocrine
system known to undergo calcium-dependent exocytosis
(Kim & Neher, 1988). These cells express L_, N-, and P-type
VDCCs (Albillos, Garcia, Olivera & Gandia, 1996), which
are sensitive to antagonists similar to those interacting with
electric organ VDCCs.
We examined ICa from chromaffin cells after they had been
exposed to IgG (1 mg ml¢) from LES patient 2 for 24 h. The
peak ICa elicited at +10 mV declined markedly to
13·3 pA pF¢ (n = 24 cells) compared with 24·5 pA pF¢
(n = 23) measured in cells incubated in control IgG, a
reduction of 46% (Fig. 5A). The current—voltage relation-
ships are unchanged by the presence of the pathogenic anti-
bodies, only the amplitude of the current is altered (Fig. 5B).
Serum from patient 1 yielded similar results (Fig. 5 C).
Type of VDCCs downregulated by LES antibodies
These experiments are based on the premise that the
receptors for the toxins are integral parts of the Ca¥
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Figure 5. Patch-clamp recordings of whole-cell ICa in bovine adrenal chromaffin cells
A, shown are representative Ca¥ currents from bovine adrenal chromaffin cells incubated with control and
LES (patient 2) IgG (2 mg ml¢) for 24 h. The 5 depolarizing voltage steps applied are shown at the top of
the panel: from the holding potential of −80 mV to −60, −10, +10, +30 and +80 mV. The maximal
current was elicited with step 3 to +10 mV. The scale bar is for both control and LES tracings.
B, current—voltage (I—V ) relationship for the cells presented in A. Notice that the maximal current occurs at
+10 mV for both cells and that the general relationship is unaltered by the presence of the LES antibodies.
C , summary data for peak ICa in bovine adrenal cells depolarized to +10 mV. Cells were exposed for 24 h to
serum from LES patient 1 (1 mg ml¢ IgG), IgG from LES patient 2 (2—3 mg ml¢ IgG), or equivalent
control serumÏIgG. The data show means ± s.e.m. (n = 31 cells for Control; n = 16 for patient 1, and
n = 24 for patient 2) and have been normalized such that the control mean is 100%. *P < 0·001 by
Student’s t test compared with control.
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channel complex. Therefore, the efficacy of a given toxin
specific to a VDCC type, applied subsequent to LES IgG
treatment, will be compromised if the pathogenic antibodies
downregulate that particular channel type. This would
allow identification of the type of VDCC which must have
been inhibited by the antibodies and thus causing a
reduction in the release of ACh from the synaptosomes.
After incubation with LES serum for 70 min, synaptosomes
were exposed to one of the three Ca¥ channel blockers for
another 20 min. Then, its ability to affect the ACh release
was assessed. We first tested the effect of ù-CgTX GVIA
(50 ìÒ) following the preincubation with LES serum
(0·5 mg ml¢ IgG; Fig. 6A). As described previously, LES
serum from patient 1 reduced the ACh release to
45·1 ± 4·3% of control (0·5 mg ml¢ normal IgG). When
these pretreated synaptosomes were incubated with
50 ìÒ ù-CgTX GVIA, the ACh release was 11·9 ± 2·6%
(n = 5) relative to the control serum. Thus, the toxin
produced an additional 33% decrease beyond that achieved
with LES serum (P < 0·001). Therefore, ù-CgTX GVIA-
sensitive component of ACh release was little affected by
LES IgG, indicating that the N-type VDCCs were not
downregulated by the autoantibodies.
Next, to examine whether LES IgG inhibits ù-AgTX IVA-
sensitive PÏQ-type VDCCs, we tested the efficacy of
ù_AgTX IVA with the same protocol. When synaptosomes
were pretreated with LES serum, ù-AgTX IVA (30 ìÒ)
was essentially ineffective in inhibiting ACh release
(Fig. 6B). In control serum-treated synaptosomes, ù-AgTX
IVA (30 ìÒ) reduced ACh release by 35·0 ± 2·7%. The
amount of ACh released in the presence of LES serum and
ù-AgTX IVA was 40·4 ± 3·4% (n = 5) of the control,
which is only an additional 4·7% inhibition and statistically
not significant. Thus, autoantibodies from LES patient 1
nearly abolished the efficacy of ù-AgTX IVA, suggesting
that ù-AgTX IVA-sensitive VDCCs are indeed down-
regulated by LES IgG.
Finally, we tested the action of calciseptine on synapto-
somes pretreated with LES antibodies. As shown in
Fig. 6 C, calciseptine (10 ìÒ) applied under this condition
diminished ACh release by an additional 13·5 ± 3·4%
(ACh released was 37·7 ± 4·1 pmol, n = 5). This extent of
inhibition is almost the same as that obtained with
application of calciseptine (10 ìÒ) to the control serum-
incubated preparations (14·7%). Thus the calciseptine-
sensitive component of ACh release was negligibly affected
by the pathological antibodies. Effects of the Ca¥ channel
antagonists on the cholinergic transmitter release from
synaptosomes preincubated with LES serum are
summarized in Table 1.
Application of IgG or serum from two additional patients to
synaptosomes confirmed the selective loss of efficacy of
ù_AgTX IVA. In the two LES preparations, ù-CgTX
GVIA was effective with an additional blockage of ACh
release by 35—38%, whereas ù-AgTX IVA blocked the
release by only 3·3—3·8%. Thus, we conclude that
pathogenic LES antibodies induce the downregulation of
PÏQ-type VDCCs of electric organ synaptosomes.
DISCUSSION
The electric organ synaptosomes from the Japanese electric
ray, Narke japonica, described herein, have recently been
used as an effective autoantigen in the induction of
experimental autoimmune Lambert—Eaton syndrome (Kim
et al. 1998). Mice and rats immunized with these cholinergic
Y. Satoh and others J. Physiol. 508.2434
Figure 6. ACh release from synaptosomes preincubated with LES IgG is less sensitive to
ù_AgTX IVA than to ù-CgTX GVIA or calciseptine
Traces of chemiluminescence output are shown. They are outputs from electric organ synaptosomes
incubated with control serum (Control), LES serum (LES), and LES serum plus one of the following Ca¥
channel antagonists: ù-CgTX GVIA (A), ù-AgTX IVA (B) and calciseptine (C). The amount of released
ACh obtained from Control and LES traces is 120·5 and 54·1 pmol, respectively. When applied following
treatment with LES serum, ù-CgTX GVIA, ù-AgTX IVA and calciseptine further reduced ACh secretion
to 10·3, 48·6 and 38·1 pmol, respectively (as depicted in the bottom traces of A, B, and C). Arrows indicate
the time when high K¤ stimulation was applied. The same control and LES sera (0·5 mg ml¢ IgG) from
patient 1 were used throughout this study.
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nerve terminals exhibit a prejunctional defect of neuro-
muscular transmission characterized by a reduction in end-
plate potential quantal content. However, the type(s) of
synaptosomal VDCCs acting as the autoantigen has not
been identified. In the present work, we have pharma-
cologically classified the VDCCs of the cholinergic terminal
synaptosomes, revealing the existence of at least three
types of Ca¥ channels: ù-CgTX-sensitive N-type, ù-AgTX
IVA-sensitive PÏQ-type and calciseptine-sensitive L-type
VDCCs. To determine the reactivity of LES IgG with the
putative Ca¥ channel antigens, we have also probed the
functional impairment of the cholinergic transmitter release
caused by the autoantibodies. These experiments prove that
the pathogenic LES IgG predominantly downregulates
ù_AgTX IVA-sensitive PÏQ-type Ca¥ channels. It is
noteworthy that this Ca¥ channel type is coupled with ACh
exocytotic secretion in electric organ synapses, as is the case
with the motor nerve terminals of the mammalian neuro-
muscular junction (Protti & Uchitel, 1993; Protti, Reisin,
Mackinley & Uchitel, 1996). These findings provide the
rationale for the use of electric organ synaptosomes as an
immunogen to develop an autoimmune animal model of
LES.
Cholinergic nerve terminals of Narke japonica electric organ
appear to be an excellent system in which to study the
specificity of LES IgG for multiple presynaptic Ca¥
channels that mediate neurotransmitter release process. The
present results demonstrate that ACh release in electric
organ synaptosomes is inhibited by acute application of
serum or IgG from LES patients. In synaptosomes
incubated with LES IgG, ionomycin-induced ACh release
was not changed from the control, suggesting that the
reduction in ACh release was not a result of an effect
downstream of Ca¥ influx through VDCCs. Thus, the
inhibition caused by the pathogenic autoantibodies is
attributed to alteration in the activity of VDCCs at the
presynaptic nerve terminal. This notion is confirmed by the
experiments showing that antibodies from two of the LES
patients, which were effective in reducing ACh release from
the synaptosomes, also inhibit ICa in bovine adrenal
chromaffin cells.
Significant variations in the time course of the effect of LES
antibodies have been reported. A reduction in
45
Ca¥ uptake
or voltage-dependent Ca¥ currents in SCLC cell lines was
only apparent after 24 h incubation with IgG and was
maximal after 1 to 4 days (De Aizpurua et al. 1988; Viglione
et al. 1995). This is in contrast with the report that half-
maximal inhibition of Ca¥ influx in SCLC cells (MB)
derived from an LES patient occurred following a 90 min
incubation (Johnston, Lang, Leys & Newsom-Davis, 1994).
The early inhibition of whole-cell ICa in bovine adrenal
chromaffin cells and an SCLC cell line occurred after 0·5 and
2 h exposures to LES IgG, respectively, (Kim & Neher,
1988; Meriney et al. 1996). In both rat and chick
synaptosomes, an incubation period lasting 1 h was
sufficient to allow LES antibody binding (Martin-Moutot et
al. 1995). The time course of the effect of LES antibodies
observed from electric organ synaptosomes (half-maximal
inhibition occurred in about 30 min, Fig. 3B) was relatively
fast and similar to that observed in some of these
preparations. Among the factors responsible for the varying
time courses is the different ‘potency’ or concentration of
pathogenic antibodies used in these studies. Additional
plausible explanation is that frequency of autoantibody cross-
linking of VDCCs (Peers et al. 1993), a phenomenon required
for antigenic modulation, may vary depending upon density
of the putative Ca¥ channels in a given preparation. The
cross-linkage may be delayed, for example, with low density
of VDCCs interacting with LES IgG, resulting in a
prolonged time course of the IgG-induced downregulation.
As isolation of large quantities of motor nerve terminals
from skeletal neuromuscular junctions is impractical,
synaptosomes from mammalian cortical synaptosomes have
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Table 1. Effects of Ca¥ channel antagonists on ACh release from synaptosomes preincubated with
LES autoantibodies
––––––––––––––––––––––––––––––––––––––––––––––
ACh release (pmol)
Pretreatment ––––––––––––––––––––––––––––––––
No antagonist ù-CgTX GVIA ù-AgTX IVA Calciseptine
––––––––––––––––––––––––––––––––––––––––––––––
Control 119·2 ± 3·5 67·2 ± 5·0 ** 77·5 ± 4·1 ** 101·7 ± 5·2 *
(100 ± 2·9%) (56·4 ± 4·2%) (65·0 ± 2·7%) (85·3 ± 4·4%)
LES 53·8 ± 5·1 14·2 ± 3·1 † 48·1 ± 4·0 37·7 ± 4·1 ‡
(45·1 ± 4·3%) (11·9 ± 2·6%) (40·4 ± 3·4%) (31·6 ± 3·4%)
––––––––––––––––––––––––––––––––––––––––––––––
**P < 0·0001 compared with the value found in control cells with no antagonist. *P < 0·05 compared
with the value found in control cells with no antagonist. †P < 0·001 compared with the value found in LES
cells with no antagonist. ‡P < 0·05 compared with the value found in LES cells with no antagonist.
Synaptosomes (30 ìg protein) were preincubated with control and LES (patient 1) serum samples
(0·5 mg ml¢ IgG), followed by incubation with Ca¥ channel antagonists. The amount of released ACh is
averaged (means ± s.e.m.) from at least 4 determinations. The percentage values, relative to the control
obtained from control cells with no antagonists, are shown in parentheses.
––––––––––––––––––––––––––––––––––––––––––––––
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been used as a model system to study the synaptic
inhibitory action of LES antibodies. In rat forebrain
synaptosomes, ù-CgTX GVIA or dihydropyridines do not
block ACh release (Hewett & Atchison, 1992) nor inhibit the
45
Ca¥ uptake by K¤-induced depolarization (Pocock, Venema
& Adams, 1992; Martin-Moutot et al. 1995). Depolarization-
induced
45
Ca¥ influx in chick synaptosomes is partially
inhibited by ù-CgTX GVIA (Pocock et al. 1992; Martin-
Moutot et al. 1995). It is unclear, however, whether these
synaptosomal preparations were previously identified as
possessing ù-AgTX IVA-sensitive PÏQ-type Ca¥ channels,
a principal channel subtype downregulated by LES IgG.
Assessment of synaptosomal Ca¥ channel function modified
by LES IgG has been inconsistent. Hewett & Atchison
(1992) found LES serum to reduce depolarization-induced
uptake of
45
Ca¥ into rat brain synaptosomes, whereas
Martin-Moutot et al. (1995) reported no apparent effect of
LES sera or IgG on
45
Ca¥ uptake in either rat or chick brain
synaptosomes. Unlike our results, inhibition by LES IgG of
45
Ca¥ influx in the brain synaptosomes required the
presence of 10% serum (Hewett & Atchison, 1992).
Remarkably, LES IgG identified as immunoprecipitating
[ÁÂÇI]ù-CgTX GVIA-labelled N-type VDCCs failed to inhibit
45
Ca¥ uptake (Martin-Moutot et al. 1995). This raises the
possibility that immunoprecipitation assay of ù-CgTX
GVIA-sensitive channels may bear no correlation with
functional impairment of that particular channel type.
Alternatively, the lack of functional effect in synaptosomes
may be attributed to the disruption of the cytoskeleton
during tissue homogenization (Martin-Moutot et al. 1995).
This, however, does not explain the positive result obtained
with ù-AgTX IVA-sensitive PÏQ-type VDCCs, which are
both immunoprecipitated and functionally inhibited by
LES IgG (Lennon et al. 1995; Viglione et al. 1995).
The present experiments provide evidence that presynaptic
inhibition of ACh release caused by LES IgG, as confirmed
with antibodies from three patients, is primarily through
ù_AgTX IVA- sensitive PÏQ-type VDCCs. It is relevant to
recognize functional similarity of these synaptosomal
channels and the presynatic Ca¥ channels at the neuro-
muscular junction: both of these channel types are engaged
in cholinergic transmitter release at a synaptic site.
Downregulation of either ù-CgTX GVIA-sensitive N-type
or calciseptine-sensitive L-type Ca¥ channels was
insignificant. Such Ca¥ channel specificity concurs with the
two recent studies demonstrating immunoprecipitation of
PÏQ-type Ca¥ channels (Lennon et al. 1995) and functional
inhibition of SCLC P-type Ca¥ channels (Viglione et al.
1995) by LES antibodies.
The apparent heterogeneity of Ca¥ channel specificities
among LES antibodies, however, has also been reported.
LES IgG was found to specifically immunoprecipitate
ù_CgTX GVIA-sensitive VDCC complex and to increase the
rate of
125
I-ù-CgTX GVIA receptor internalization and
degradation (Lennon & Lambert, 1989; Sher et al. 1989). In
a variety of neuroendocrine and neuronal cell types, the
pathogenic antibodies reportedly inhibit ICa carried by
N_type (Grassi et al. 1994), L-type (Peers et al. 1990; Grassi
et al. 1994) and T-type (Grassi et al. 1994; Garcia & Beam,
1996) VDCCs. A patch-clamp study of an SCLC cell line
treated with LES IgG suggests downregulation of multiple
types of Ca¥ channels (Meriney et al. 1996). In view of the
role of PÏQ type Ca¥ channels in evoked transmitter release
at the human neuromuscular junction (Protti et al. 1996), it
is logical to expect that LES autoantibodies pathologically
target this particular channel type. The present finding that
LES IgG specifically downregulates PÏQ-type VDCCs is
consistent with this expectation. The role in pathogenesis of
the antibodies immunoprecipitating or inhibiting the
function of ù-CgTX GVIA-sensitive VDCCs, a channel type
not found at the human and mouse neuromuscular junctions,
is yet to be determined. As the autonomic dysfunction is a
common clinical symptom of LES (Mamdani, Walsh, Rubino,
Brannegan & Hwang, 1985), anti-N-type Ca¥ channel anti-
bodies may potentially interfere with transmitter release at
the autonomic synapses. In a recent study of passively
transferred LES in mice, the function of sympathetic and
parasympathetic nerve terminals was assessed, but no
evidence supporting such pathophysiology was found
(Waterman, Lang & Newsom-Davis, 1997). In the majority
of animals tested, the defect of autonomic synaptic
transmission did not arise from inhibition of N-type Ca¥
channels but due to the inhibition of PÏQ-type channels.
It has been proposed that a synaptic protein other than a
Ca¥ channel is the autoantigen in LES. A vesicle-associated
protein, synaptotagmin was asserted as a putative target
based on in vitro immunoprecipitation studies (Leveˆque et
al. 1992). In addition, rats immunized with peptides of
synaptotagmin residues (20 to 53 inclusive) develop a
reduction in nerve-evoked ACh release at the neuromuscular
junction (Takamori, Hamada, Komai, Takahashi & Yoshida,
1994). This proposition contrasts with the Western blot
analysis indicating that none of the sera from fourteen
LES patients, examined for their ability to recognize the
nerve terminal proteins, reacted with pure recombinant
synaptotagmin or syntaxin (Hajela & Atchison, 1995). Our
observation that ionomycin triggers the equal amount of
ACh release from synaptosomes incubated with LES and
control serum (Fig. 4) also fails to support this hypothesis.
Thus it remains to be resolved whether synaptotagmin is
indeed a co-molecular target of LES antibodies andÏor plays
any role in LES pathogenesis.
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